On November 27th, the plenary session of the 12th Pharmacopoeia Committee Executive Committee was held in Beijing to review and approve the 2025 version of the Pharmacopoeia of the People's Republic of China (Draft), and to deploy and promote the implementation of the new version of the Pharmacopoeia. Li Li, Secretary of the Party Group and Director of the National Medical Products Administration, and Chairman of the 12th Pharmacopoeia Committee, attended the meeting and delivered a speech. Wang Zhiyong, member of the Party Group, Deputy Director, and Vice Chairman of the National Administration of Traditional Chinese Medicine, reported on the review of the 2025 edition of the Pharmacopoeia. Zhao Junning, member of the Party Group, Deputy Director, and Vice Chairman of the National Medical Products Administration, announced the list of members of the 12th Pharmacopoeia Committee after adjustment. Huang Guo, member of the Party Group, Deputy Director, and Vice Chairman of the National Medical Products Administration, presided over the meeting.

Li Li pointed out that drug standards are the yardstick for drug quality and safety, and pharmacopoeia is the core of the national drug standard system. With the joint efforts of all members, the preparation of the 2025 edition of the Pharmacopoeia has paid more attention to absorbing innovative achievements, improving the structure and style, strictly abiding by the safety bottom line, and standardizing the preparation procedures. The scientificity, systematicness, safety, and standardization of the Pharmacopoeia have been significantly improved, forming a complete drug standard system covering Chinese herbal materials, Chinese herbal decoction pieces, traditional Chinese patent medicines and simple preparations, chemicals, biological products, pharmaceutical excipients, drug packaging materials and other categories, and successfully completing the objectives and tasks of the preparation of the outline.

Li Li emphasized that the promulgation and implementation of the new version of the pharmacopoeia will build a more solid "protective wall" for public drug safety, provide a clearer "compass" for promoting high-quality development of the pharmaceutical industry, and build a more convenient "new bridge" for China's drugs to go international. We must resolutely implement General Secretary Xi Jinping's "four strictest" requirements, coordinate to ensure high-level drug safety and promote high-quality development of the pharmaceutical industry, and strive to create a new situation in drug standard work. We must actively promote the construction of drug standard system and management capacity, conduct in-depth scientific research on drug standards, strengthen the construction of drug standard talent team, and improve the performance level of pharmacopoeia committee members. Secondly, we need to comprehensively enhance the overall level of national drug standards, improve the dynamic management mechanism of standards, and enhance the international recognition and influence of Chinese drug standards. We must solidly carry out the implementation of the new version of the Pharmacopoeia, strengthen publicity, training, and policy interpretation, and better play the fundamental and guiding role of drug standards in strengthening efficient supervision, ensuring high-level safety, and promoting high-quality development.